Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03865420

Amyotrophic Lateral Sclerosis (ALS) Families Project

Status
Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Columbia University · Academic / Other
Sex
All
Age
18 Years – 105 Years
Healthy volunteers
Not accepted

Summary

This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses. This study provides genetic counseling and testing to help participants understand and manage their risk and determine if they want to learn their genetic status. This study will follow unaffected ALS gene mutation carriers on an annual basis to gather essential information that will ultimately help researchers develop novel therapies for the prevention and treatment of ALS.

Detailed description

Approximately 10% of people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's Disease, have a family history of ALS or a related condition called frontotemporal dementia (FTD). In most of these familial cases, and a significant number of "sporadic" patients with no family history, a mutation is present in one of a growing number of genes that have been associated with ALS and/or FTD. The ALS Families Project will study unaffected carriers of ALS/FTD-associated gene mutations to investigate the first steps in the disease process that leads to motor neuron degeneration, with the goal of identifying early disease targets and points of intervention to slow or stop disease onset and progression. Unaffected individuals who have either a family member with a known ALS/FTD-associated gene mutation or have a strong family history of ALS and FTD are invited to participate in the ALS Families Project. For those who enroll, research visits will occur every 6-12 months.

Conditions

Timeline

Start date
2018-09-11
Primary completion
2027-01-01
Completion
2027-01-01
First posted
2019-03-06
Last updated
2026-01-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03865420. Inclusion in this directory is not an endorsement.